StageZero Life Sciences has completed its acquisition of Health Clinics Limited, creating a vertically-integrated healthcare company with advanced diagnostic and telemedicine capabilities. This strategic move involves the purchase of Clinics Operations Limited and Health Clinics USA Corp., enhancing StageZero's ability to provide early detection and intervention for cancer and chronic diseases. The total share issuance includes 12.4 million common shares, with additional shares contingent upon certain milestones. The acquisition aims to bolster revenue and expand patient care services.
StageZero Life Sciences has announced a share purchase agreement to acquire Clinics Operations Limited, enhancing its capabilities in early disease diagnosis and prevention. The acquisition is expected to generate approximately $4 million in annual revenue and provides immediate accretion to StageZero. The deal allows access to Care Oncology's extensive network of healthcare professionals and positions the company favorably within the growing liquid biopsy diagnostic market. The transaction is set to close later this month, pending TSX approval.
StageZero Life Sciences announced a new ticker symbol, SZLSF, for its securities on the OTC Markets effective July 8, 2021. This change aligns the company’s branding with its marketing strategy as it expands its presence in the US market. James Howard-Tripp, the Chairman and CEO, expressed confidence in the new ticker enhancing the company's brand. StageZero specializes in early disease detection, offering multi-cancer blood tests and COVID-19 testing through a CAP accredited laboratory.